# The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

> **NCT03246451** · NA · COMPLETED · sponsor: **University Hospital, Gentofte, Copenhagen** · enrollment: 15 (actual)

## Conditions studied

- Glucose Metabolism Disorders

## Interventions

- **DRUG:** Placebo Oral Tablet
- **DRUG:** Metformin
- **DRUG:** Saline
- **DRUG:** Exendin (9-39)

## Key facts

- **NCT ID:** NCT03246451
- **Lead sponsor:** University Hospital, Gentofte, Copenhagen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2017-12-10
- **Final completion:** 2017-12-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03246451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03246451, "The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03246451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*